CHAPTERS 1-4 provide extensive foundation materials, including the
basic principles of pharmacology, neurophysiology and neuroanatomy,
synaptic transmission, and methods in psychopharmacology.
1. Principles of Pharmacology
*New section on therapeutic drug monitoring
*New material on pharmacogenetics/personalized medicine
*Expanded section on transdermal drug delivery and viral vectors
for gene therapy
2. Structure and Function of the Nervous System
*New section on epigenetics
*Introductory material on neurotrophic factors
*New section on comparing mammalian brains
*New box on stem cells
*New box on the HPA axis
3. Chemical Signaling by Neurotransmitters and Hormones
*New opening vignette on the discovery of chemical transmission in
the brain
*Discussion of 'volume' vs. 'wiring' transmission
*New section on drug-induced synaptic plasticity
*New box on sex hormones and drug abuse
4. Methods of Research in Psychopharmacology
*Revised order to introduce behavioral methods before
neurobiological methods
*Expanded section on translational research
*New material on pharmacological MRI
*New boxes showing how drug discrimination and transgenic mouse
models are used in research
CHAPTERS 5-8 describe the basic biochemistry, anatomy, and
functional contributions of key neurotransmitter systems.
5. Catecholamines
*New opening vignette on the use of stimulant drugs as study
aids
*New box on genetic mutations in humans that interfere with
dopamine synthesis
*Expanded coverage of the behavioral functions of the noradrenergic
system
6. Serotonin
*New opening vignette describing a case report of the ' serotonin
syndrome'
*New box on 'ecstasy' as a recreational drug, neurotoxin, and
potential medication
*Discussion of the phenotypic characteristics of serotonin
transporter knockout mice and of transgenic mice lacking central
serotonergic neurons
*Expanded coverage of serotonin receptors and their functions
*New box on the role of serotonin in aggressive behavior
7. Acetylcholine
*New opening vignette describing the discovery and subsequent study
of curare
*Expanded coverage of cholinergic pathways, receptors, and
physiological functions
*New box on the role of acetylcholine in cognition
8. Glutamate and GABA
*Expanded coverage of vesicular and plasma membrane glutamate
transporters
*Discussion of the potential therapeutic use of metabotropic
glutamate receptor agonists in treating schizophrenia
*Discussion of ampakines as cognitive enhancers
*Updated box on long-term potentiation
*New box on the involvement of GABA in epilepsy
CHAPTERS 9-17 summarize the main features of addiction and cover
all major abused drugs from the standpoint of prevalence of use,
subjective effects, mechanisms of action, and addictive
potential.
9. Drug Abuse and Addiction
*Completely reorganized with better integration of the various
factors that contribute to addiction
*Coverage of the new DSM-5 criteria for substance use disorder
*New boxes discussing behavioral (non-drug) addictions and the role
of dopamine in reward
*Expanded and updated coverage of addiction neurobiology
10. Alcohol
*Expanded section on fetal alcohol syndrome
*New discussion of extrasynaptic GABA receptors
*New section on the role of stress and alcohol consumption
*New material on alcoholism treatments
*New box on gender differences in the effects of alcohol
*New Web Box on Alcoholics Anonymous
11. The Opioids
*New material on nociceptin/orphanin FQ and its receptor
*New section on the role of opioids in other forms of pain control:
acupuncture, dual inhibition of peptidases, and gene therapy
*New section on the use of acupuncture for opiate withdrawal
*New material on the use of buprenorphine maintenance and vaccines
for addiction treatment
*New box on oxycontin
12. Psychomotor Stimulants: Cocaine and the Amphetamines
*New box on the relative reinforcing efficacy of cocaine vs.
alternative reinforcers
*Updated coverage of the mechanisms of cocaine action
*New information on animal models of escalated cocaine
self-administration
*Updated and expanded coverage of the development of cocaine
addiction and of neuroimaging studies of cocaine users
*New coverage of synthetic cathinone derivatives marketed as 'bath
salts'
13. Nicotine and Caffeine
*New opening vignette on the discovery of tobacco by Columbus
*Updated discussion of the role of nicotine vs. conditioning
factors in the subjective effects of smoking
*Updated coverage of the cognitive effects of nicotine, the
mechanisms of nicotine reinforcement, and nicotine tolerance
*New box on the progression from occasional to regular smoking,
including the Hooked on Nicotine Checklist developed to assess the
early stages of nicotine dependence
*New box on the health risks of caffeine-containing energy
drinks
14. Marijuana and the Cannabinoids
*Updated coverage of cannabinoid receptors
*New information on the behavioral and physiological functions of
the endocannabinoid system
*Updated discussion of the behavioral and health-related effects of
acute and chronic cannabis use
*New box on the relationship between early heavy marijuana use and
later risk for developing psychosis
*New information on designer cannabinoids marketed as ' K2' or
'Spice'
15. Hallucinogens, PCP, and Ketamine
*New coverage of Salvia divinorum including subjective effects and
mechanism of action
*New information on instruments like the Altered States of
Consciousness rating scale used to study the subjective effects of
hallucinogenic substances
*Updated information on the mechanisms underlying
hallucinogenesis
*Expanded discussion of the adverse effects of repeated PCP or
ketamine exposure
*New information on potential therapeutic applications of
ketamine
16. Inhalants, GHB, and Anabolic Androgenic Steroids
*Updated coverage of the effects of acute and chronic inhalant
use
*New information on the health risks of inhalants, including a
proposed fetal solvent syndrome to describe craniofacial anomalies
seen in infants exposed to inhalants prenatally
*Expanded and updated coverage of the mechanisms of action of GHB,
GHB abuse, and the therapeutic use of GHB
*Updated information on anabolic steroid use by amateur and
professional athletes
*Expanded and updated coverage of the mechanism of anabolic steroid
action on muscle growth and the health risks of anabolic steroid
use
NEW CHAPTER!
17. Environmental Neurotoxicants and Endocrine Disruptors
CHAPTERS 18-21 cover psychiatric and neurodegenerative disorders,
presenting symptoms, proposed etiology, and therapeutic approaches
(especially pharmacotherapies) for each.
18. Anxiety Disorders: Sedative-Hypnotic and Anxiolytic Drugs
*Greatly expanded section on the neurobiology of anxiety
*Enhanced section on the role of catecholamines, GABA, and
serotonin in anxiety
*New section on the interaction of genetics and the environment in
determining anxiety
*New section on the role of stress-induced epigenetic changes in
anxiety disorders
*New material on gender differences in the response to stress
*New Web Box on new therapeutic targets
19. Affective Disorders: Antidepressants and Mood Stabilizers
*Expanded section on animal models
*Expanded discussion of the role of antidepressant-induced
enhancement of neurogenesis
*New material on tryptophan depletion challenge and polymorphisms
of the serotonin transporter
*Expanded section on third-generation antidepressants: ketamine,
galanin, and agomelatine
*Expanded and updated material on valproate and carbamazepine
20. Schizophrenia: Antipsychotic Drugs
*Greater emphasis on cognitive dysfunction throughout
*Enhanced section on the role of genetics
*Further development of the hypoglutamate model
*Expanded section on second-generation therapeutics
*New section on efforts to treat the cognitive symptoms
*New box on epigenetic changes and the risk for schizophrenia
*New box on a neurodevelopmental animal model
NEW CHAPTER!
21. Neurodegenerative Diseases
Jerrold S. Meyer is Professor Emeritus of Psychology and former
Director of the interdepartmental Neuroscience and Behavior Program
at the University of Massachusetts, Amherst. He did his graduate
work under Dr. Robert Bowman at the University of Wisconsin,
receiving his Ph.D. in 1974, and he was a postdoctoral fellow with
Dr. Bruce McEwen at Rockefeller University and with Dr. William
Boggan at the Medical University of South Carolina. He is the
author or coauthor of over 120 articles and chapters in the fields
of neuropharmacology and neuroendocrinology, and coauthored the
first edition of the present text with Linda Quenzer as well as
Principles of
Neuropsychopharmacology (1997) with Robert Feldman and Linda
Quenzer. Dr. Meyer is a member of the Board of Directors of the
International Drug Abuse Research Society and the Editorial Board
of the journal Neurotoxicology and Teratology. He is a past
President of the Neurobehavioral Teratology Society. His current
research, funded by the National Institutes of Health, focuses on
stress and psychopathology in both humans and animal models. He has
also recently conducted
numerous studies on the neurotoxic and behavioral effects of the
abused drug MDMA ("ecstasy").
Linda F. Quenzer is Adjunct Professor of Psychology and
Neuroscience at the University of Hartford. She received her Ph.D.
from the University of Massachusetts, Amherst, in 1974 with Dr.
Robert S. Feldman and she was an NIMH postdoctoral fellow in the
Laboratory of Preclinical Pharmacology with Dr. Norton Neff. During
her appointment in the Departments of Pharmacology and Psychiatry
at the University of Connecticut Medical School, she received a
Career Development Award from
the Pharmaceutical Manufacturers Association Foundation. Dr.
Quenzer has extensive teaching experience in the areas of
psychobiology and neuropsychopharmacology at the undergraduate,
graduate, and postgraduate levels.
Her previous collaborations with Sinauer Associates include
Fundamentals of Neuropsychopharmacology (1984, with Robert Feldman)
and Principles of Neuropsychopharmacology (1997, with Robert
Feldman and Jerrold Meyer). Her current interests concern the role
of the HPA axis, hippocampal atrophy, and neurogenesis in
psychiatric disorders.
Ask a Question About this Product More... |